Photo from Nitin Jain/X
May 22, 2024, 01:53
Nitin Jain: Looking forward to presenting phase 2 trial of frontline treatment for patients with CLL at EHA 2024
Nitin Jain, Professor of the Department of Leukemia at MD Anderson Cancer Center, shared on X:
“Looking forward to presenting investigator initiated phase 2 trial of time-limited pirtobrutinib plus venetoclax plus obinutuzumab as frontline treatment for patients with CLL at EHA 2024.” .
Read further.
Source: Nitin Jain/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18